Genital Warts (Condyloma Acuminatum) Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Verrica Pharma, Novan, Inc., Graceway Pharma, Novartis, MediGene

DelveInsight's "Genital Warts Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Genital Warts, historical and forecasted epidemiology as well as the Genital Warts market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Genital Warts market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Genital Warts Market Forecast
https://www.delveinsight.com/sample-request/genital-warts-condyloma-acuminatum-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Genital Warts Market Report:
• The Genital Warts market size was valued ~USD 860 Million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In 2023, there were 860,000 reported incident cases of genital warts across the 7MM. This number is projected to undergo significant changes by 2034.
• In 2023, approximately 547,000 new cases of genital warts were reported in the United States.
• In the United States, when the incident population of genital warts was categorized by anatomical location in 2023, there were nearly 257,000 cases reported, representing the highest number of cases. This was followed by approximately 164,000 cases with unspecified locations and 84,000 cases for the cervix.
• In the EU4 and the UK, Germany reported the highest number of incident cases of genital warts, with about 75,000 cases, followed by France and the UK, each with around 55,000 cases. Projections suggest a significant change in these numbers by 2034.
• In 2023, Japan reported approximately 37,000 incident cases of genital warts, making it the lowest among the 7MM. This number is anticipated to decline further by 2034.
• In Japan, the number of males diagnosed with genital warts exceeds that of females. In 2023, there were approximately 15,000 reported cases among females, compared to around 22,000 cases in the male population.
• Key Genital Warts Companies: Medicis Pharmaceuticals, Aresus Pharma, Tamir Biotechnology (Orgenesis), Verrica Pharmaceutical, Novan, Inc., Graceway Pharmaceuticals, LLC, Novartis, MediGene, Anaconda Pharma, G&E Herbal Biotechnology , pHion Therapeutics, KinoPharma, Cassiopeia, Innovax, and others
• Key Genital Warts Therapies: Imiquimod, Veregen (Polyphenon E), Onconase, VP-102, SB207, NVN1000, Aldara, imiquimod cream, Polyphenon E, AP611074, and others
• The Genital Warts market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Genital Warts pipeline products will significantly revolutionize the Genital Warts market dynamics.

Genital Warts Overview
Genital warts (also known as anogenital warts, condyloma acuminata, condylomas) are benign proliferative lesions caused by human papillomavirus (HPV) types 6 and 11, which are found in >95% of lesions. Genital warts (GWs) are transmitted by having sexual contact with someone who already has them and may be found on the outside of genitals. Some types, which cause cancer, result in the growth of lesions on a woman's cervix

Get a Free sample for the Genital Warts Market Report:
https://www.delveinsight.com/report-store/genital-warts-condyloma-acuminatum-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Genital Warts Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Genital Warts Epidemiology Segmentation:
The Genital Warts market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Genital Warts
• Prevalent Cases of Genital Warts by severity
• Gender-specific Prevalence of Genital Warts
• Diagnosed Cases of Episodic and Chronic Genital Warts

Download the report to understand which factors are driving Genital Warts epidemiology trends @ Genital Warts Epidemiology Forecast
https://www.delveinsight.com/sample-request/genital-warts-condyloma-acuminatum-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Genital Warts Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Genital Warts market or expected to get launched during the study period. The analysis covers Genital Warts market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Genital Warts Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Genital Warts Therapies and Key Companies
• Imiquimod: Veregen (Polyphenon E): Aresus Pharma
• Onconase: Tamir Biotechnology (Orgenesis)
• VP-102: Verrica Pharmaceutical
• SB207: Novan

Discover more about therapies set to grab major Genital Warts market share @ Genital Warts Treatment Market
https://www.delveinsight.com/sample-request/genital-warts-condyloma-acuminatum-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Genital Warts Market Drivers
• Increasing prevalence of genital warts
• Implementation of HPV vaccination programs
• Potential emerging trials
• Impact of COVID-19

Genital Warts Market Barriers
• Lack of satisfactory cure in the HPV treatment
• Lack of awareness among some sections of society
• Economically unviable vaccination treatment for adults

Scope of the Genital Warts Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Genital Warts Companies: Medicis Pharmaceuticals, Aresus Pharma, Tamir Biotechnology (Orgenesis), Verrica Pharmaceutical, Novan, Inc., Graceway Pharmaceuticals, LLC, Novartis, MediGene, Anaconda Pharma, G&E Herbal Biotechnology , pHion Therapeutics, KinoPharma, Cassiopeia, Innovax, and others
• Key Genital Warts Therapies: Imiquimod, Veregen (Polyphenon E), Onconase, VP-102, SB207, NVN1000, Aldara, imiquimod cream, Polyphenon E, AP611074, and others
• Genital Warts Therapeutic Assessment: Genital Warts current marketed and Genital Warts emerging therapies
• Genital Warts Market Dynamics: Genital Warts market drivers and Genital Warts market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Genital Warts Unmet Needs, KOL's views, Analyst's views, Genital Warts Market Access and Reimbursement

To know more about Genital Warts companies working in the treatment market, visit @ Genital Warts Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/genital-warts-condyloma-acuminatum-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Genital Warts Market Report Introduction
2. Executive Summary for Genital Warts
3. SWOT analysis of Genital Warts
4. Genital Warts Patient Share (%) Overview at a Glance
5. Genital Warts Market Overview at a Glance
6. Genital Warts Disease Background and Overview
7. Genital Warts Epidemiology and Patient Population
8. Country-Specific Patient Population of Genital Warts
9. Genital Warts Current Treatment and Medical Practices
10. Genital Warts Unmet Needs
11. Genital Warts Emerging Therapies
12. Genital Warts Market Outlook
13. Country-Wise Genital Warts Market Analysis (2020-2034)
14. Genital Warts Market Access and Reimbursement of Therapies
15. Genital Warts Market Drivers
16. Genital Warts Market Barriers
17. Genital Warts Appendix
18. Genital Warts Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Genital Warts Epidemiology https://www.delveinsight.com/report-store/genital-warts-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Genital Warts Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Genital Warts epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight

Orthopedic Trauma Devices Market https://www.delveinsight.com/report-store/orthopedic-trauma-devices-market
Global Orthopedic Trauma Devices Market was valued at USD 7.01 billion in 2023, growing at a CAGR of 6.43% during the forecast period from 2024 to 2030 to reach USD 10.15 billion by 2030. The demand for orthopedic trauma devices is witnessing growth due to the rising number of accident and trauma cases, growing prevalence of degenerative bone disorders, the rising number of sports-related injuries, rising demand for technologically advanced products, and increasing geriatric population are expected to drive product demand in the global orthopedic trauma devices market.

Acute Ischemic Stroke Market
https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market
DelveInsight's 'Acute Ischemic Stroke Market Insights, Epidemiology, and Market Forecast - 2032' report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of acute ischemic stroke in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Advanced Wound Care Market
https://www.delveinsight.com/report-store/advanced-wound-care-market
As per DelveInsight, the global Advanced Wound Care Market was valued at USD 10.44 billion in 2023, growing at a CAGR of 10.82% during the forecast period from 2024 to 2030, to reach USD 19.29 billion by 2030. The demand for advanced wound care is predominantly associated with the rising incidence of chronic wounds associated with various chronic disorders such as diabetes, and cancer, and also with the rising incidence of active wounds comprising burns, and surgical wounds, among others

Alcohol Use Disorder Market
https://www.delveinsight.com/report-store/alcohol-use-disorder-market
DelveInsight's "Alcohol Use Disorder (AUD) Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of AUD, historical and forecasted epidemiology, as well as the AUD market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
DelveInsight's "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), historical and forecasted epidemiology as well as the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.